title: Antitumor activity of a combination of rAd2p53 adenoviral gene therapy and radiotherapy in esophageal carcinoma.
abstract: The objective of this study was to determine if a combination of recombinant adenovirus 2 p53 (rAd2p53) gene therapy and radiotherapy would have significantly improved outcome from esophageal carcinoma when compared to radiotherapy (RT) alone. Forty-five patients diagnosed with esophageal carcinoma (confirmed squamous cell carcinoma) were randomly assigned to one of two study arms: treatment group: rAd2p53 gene therapy + RT (n = 22); and control group: radiotherapy (n = 23). For the treatment group, rAd2p53 was injected into multiple areas of the lesion once a week for 6 weeks avoiding deep ulcers points. RT was administered after 3 days of injection of rAd2p53. Patients in the control group only received radiotherapy. The overall response rate was significantly higher in the treatment group than in control group (P < 0.05). Furthermore, the complete response rate was 3 times higher in the treatment group than in the control group (P < 0.05). Transient fever and pain at injection site were the only side effects mentioned in the treatment group. In conclusion, this recombinant virus-RT combination is significantly more beneficial in palliation than RT alone, with minor side affects. However, its role as neoadjuvant therapy prior to surgical resection needs to be further investigated.
authors.affiliation: Department of Oncology, First Affiliated Hospital of Xinxiang Medical University, Weihui, 453100, Henan, China. lupingdoctor@126.com
authors.forename: Ping
authors.initials: P
authors.lastname: Lu
authors.forename: Xiaoyu
authors.initials: X
authors.lastname: Yang
authors.forename: Yanmei
authors.initials: Y
authors.lastname: Huang
authors.forename: Zhihong
authors.initials: Z
authors.lastname: Lu
authors.forename: Zhanhui
authors.initials: Z
authors.lastname: Miao
authors.forename: Qiudong
authors.initials: Q
authors.lastname: Liang
authors.forename: Yanli
authors.initials: Y
authors.lastname: Zhu
authors.forename: Qingxia
authors.initials: Q
authors.lastname: Fan
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000532:radiotherapy* / Q000628:therapy*; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000235:genetics / Q000532:radiotherapy* / Q000628:therapy*; D005260:Female; D016158:Genes, p53; D015316:Genetic Therapy / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000235:genetics; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins